


TOBIAS WINKLER

Group Leader Musculoskeletal System | Nominee Voting Member



Scientific Development/ CV:

Human Medicine and PhD at the University of Vienna 2002/2007

Clinical Education at the CMSC, Charité since 2004

Habilitation Cell Therapy in Muscle Trauma, Charité 2014

W2-Professor Regenerative Orthopedics and Traumatology BIH/Charité 2020

Expertise:

Spezielle Orthopädische Chirurgie und Spezielle Unfallchirurgie

Arthroplasty, reconstructive joint surgery, trauma surgery

Development of musculoskeletal ATMPs from preclinics to clinical studies

Translation of regenerative innovations to musculoskeletal surgical approaches

Treatment of periprosthetic infections


Relevant Projects/ Highlights:

EU Horizon 2020 HIPGEN Phase III Study: Allogeneic placental cell therapy for muscle injury to improve mobilisation in hip fracture patients

ILOBONE/CD31+ Phase I/IIa studies for humeral head fracture treatment, PROTO Phase I/IIa study for allogeneic therapy of knee osteoarthritis

TOBIAS WINKLER

Group Leader Musculoskeletal System | Nominee Voting Member



To my mind, the **BCRT** is *the central institution* within Charité and now BIH **living Translation of basic research findings into patient benefits**. It has already established or is about to form **enabling structures** for this task **unique** for our **clinical and research environment**.

My personal aim is to **identify and support promising and successful enablers for clinical translation**. For me **as a clinical researcher**, working in the outpatient department, the operating room and the lab, it is of **utmost importance to strengthen** also the **clinical view** on our projects and **support scientists** in early stages with **input from the medical perspective**.